
PB 81 of 2017
National Health (Pharmaceutical Benefits Scheme- Exempt items - Section 84AH) Determination 2017
National Health Act 1953
I, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 84AH of the National Health Act 1953.
Dated 19 September 2017
LISA LA RANCE
Assistant Secretary
Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name of Instrument
(1) This instrument is the National Health (Pharmaceutical Benefits Scheme-Exempt items - Section 84AH) Determination 2017.
(2) This instrument may also be cited as PB 81 of 2017.
2 Commencement
This instrument commences on the date of registration on the Federal Register of Legislation.
3 Revocation
The National Health Act 1953 – Determination under section 84AH- Exempt items (PB 58 of 2007) is revoked.
4 Authority
This Determination is made under section 84AH of the National Health Act 1953 (the Act).
5 Definitions
In this Determination:
pharmaceutical item has the meaning given by section 84AB of the Act.
Note: Terms used in this Determination have the same meaning as in the Act – see section 13 of the Legislation Act 2003. These terms include:
6 Exempt items
The pharmaceutical items identified in the Schedule are exempt from statutory price reductions and price disclosure requirements under Division 3A and 3B of Part VII of the Act.
Schedule
| ||
Listed Drug | Form (strength, type, size, etc.) | Manner of administration |
|
|
|
Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral |
Amoxycillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral |
Artemether with Lumefantrine | Tablet (dispersible) 20 mg‑120 mg | Oral |
Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15mL | Oral |
Atenolol | Oral solution 50 mg in 10 mL, 300 mL | Oral |
Captopril | Oral solution 5 mg per mL, 95 mL | Oral |
Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL | Oral |
Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the ear |
Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral |
Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral |
Clonazepam | Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent) | Injection |
Clozapine | Oral liquid 50 mg per mL, 100 mL | Oral |
Cefuroxime | Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL | Oral |
Cyclosporin | Oral liquid 100 mg per mL, 50 mL | Oral |
Cyclosporin | Capsule 10 mg | Oral |
Cyclosporin | Solution concentrate for I.V. infusion 50 mg in 1 mL | Injection |
Diazepam | Injection 10 mg in 2mL | Injection |
Diazepam | Oral liquid 1 mg in 1 mL, 100 mL | Oral |
Diclofenac | Suppository containing diclofenac sodium 100 mg | Rectal |
Digoxin | Paediatric oral solution 50 micrograms per mL, 60 mL | Oral |
Efavirenz | Oral solution 30 mg per mL, 180 mL | Oral |
Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral |
Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral |
Frusemide | Oral solution 10 mg per mL, 30 mL | Oral |
Glyceryl Trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual |
Hydrocortisone | Tablet 4 mg | Oral |
Hydromorphone | Oral liquid containing hydromorphone hydrochloride 1 mg per mL, 473 mL | Oral |
Indomethacin | Suppository 100 mg | Rectal |
Levodopa with Carbidopa | Tablet 200 mg‑50 mg (anhydrous) (modified release) | Oral |
Mercaptopurine | Oral suspension 20 mg per mL, 100 mL | Oral |
Methadone | Oral liquid containing methadone hydrochloride 25 mg per 5mL, 200 mL | Oral |
Methadone | Injection containing methadone hydrochloride 10 mg in 1 mL | Injection |
Metronidazole | Suppositories 500 mg, 10 | Rectal |
Metronidazole | Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL | Oral |
Mycophenolic Acid | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral |
Naproxen | Oral suspension 125 mg per 5mL, 474 mL | Oral |
Nevirapine | Oral suspension 50 mg (as hemihydrate) per 5 mL, 240 mL | Oral |
Ondansetron | Syrup, 4 mg (as hydrochloride dihydrate) per 5 mL, 50mL | Oral |
Oxycodone | Oral solution containing oxycodone hydrochloride 1 mg per mL, 250 mL | Oral |
Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral |
Paracetamol | Oral liquid 120 mg per 5 mL, 100 mL | Oral |
Paracetamol | Oral liquid 240 mg per 5 mL, 200 mL | Oral |
Paracetamol | Suppositories 500 mg, 24 | Rectal |
Prochlorperazine | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL | Injection |
Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral |
Risperidone | Oral solution 1mg per mL, 100 mL | Oral |
Roxithromycin | Tablet for oral suspension 50 mg | Oral |
Salbutamol | Oral solution 2 mg (as sulfate) per 5 mL, 150 mL | Oral |
Salbutamol | Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth |
Terbinafine | Cream containing terbinafine hydrochloride 10 mg per g, 15 g | Application |
Tramadol | Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL | Oral |
Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL | Oral |
Valproic Acid | Tablet, crushable, containing sodium valproate 100 mg | Oral |
Valproic Acid | Oral liquid containing sodium valproate 200 mg per 5mL, 300 mL | Oral |
Valproic Acid | Oral solution containing sodium valproate 200 mg per 5mL, 300 mL | Oral |
Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral |